Rv3802c in Tuberculosis Therapeutics

Abstract

The recent upsurge of life-threatening multidrug- and extreme drug- resistant tuberculosis along with HIV co-infection urge the need of new drug targets and drugs to cripple the survival and infection of Mycobacterium tuberculosis. The current scenario of tuberculosis might be dealt by targeting pathogen’s enzymes that participate in both cell wall and lipid metabolism.